{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:03:06Z","timestamp":1792738986570,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100010090","name":"wchri","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010090","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00204-021-03184-z","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T10:02:40Z","timestamp":1637316160000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1291-497X","authenticated-orcid":false,"given":"Omar","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-3546","authenticated-orcid":false,"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"issue":"1","key":"3184_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/nat.2018.0756","volume":"29","author":"A Aartsma-Rus","year":"2019","unstructured":"Aartsma-Rus A, Goemans N (2019) A sequel to the eteplirsen saga: eteplirsen is approved in the united states but was not approved in Europe. Nucl Acid Ther 29(1):13\u201315. https:\/\/doi.org\/10.1089\/nat.2018.0756","journal-title":"Nucl Acid Ther"},{"issue":"2","key":"3184_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","volume":"34","author":"A Aartsma-Rus","year":"2006","unstructured":"Aartsma-Rus A, Van Deutekom JCT, Fokkema IF, Van Ommen GJB, Den Dunnen JT (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34(2):135\u2013144. https:\/\/doi.org\/10.1002\/mus.20586","journal-title":"Muscle Nerve"},{"issue":"5","key":"3184_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/nat.2017.0682","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Straub V, Hemmings R, Haas M, Schlosser-Weber G, Stoyanova-Beninska V, Mercuri E, Muntoni F, Sepodes B, Vroom E, Balabanov P (2017) development of exon skipping therapies for duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucl Acid Ther 27(5):251\u2013259. https:\/\/doi.org\/10.1089\/nat.2017.0682","journal-title":"Nucl Acid Ther"},{"issue":"26","key":"3184_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000015858","volume":"98","author":"LN Alfano","year":"2019","unstructured":"Alfano LN, Charleston JS, Connolly AM, Cripe L, Donoghue C, Dracker R, Dworzak J, Eliopoulos H, Frank DE, Lewis S, Lucas K, Lynch J, Milici AJ, Flynt A, Naughton E, Rodino-Klapac LR, Sahenk Z, Schnell FJ, Young GD, Lowes LP (2019) Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine 98(26):e15858. https:\/\/doi.org\/10.1097\/md.0000000000015858","journal-title":"Medicine"},{"key":"3184_CR5","first-page":"445","volume":"449","author":"Z Aloysius","year":"1996","unstructured":"Aloysius Z, Pramono D, Takeshima Y, Alimsardjono H, Ishii A, Takeda S, Matsuo M (1996) Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence expression because they offer the exciting possibility of blocking the expressi. Biochem Biophys Res Commun 449:445\u2013449","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"3184_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm1345","volume":"12","author":"J Alter","year":"2006","unstructured":"Alter J, Lou F, Rabinowitz A, Yin HF, Rosenfeld J, Wilton SD, Partridge TA, Qi LL (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12(2):175\u2013177. https:\/\/doi.org\/10.1038\/nm1345","journal-title":"Nat Med"},{"issue":"12","key":"3184_CR7","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1093\/brain\/awr291","volume":"134","author":"K Anthony","year":"2011","unstructured":"Anthony K, Cirak S, Torelli S, Tasca G, Feng L, Arechavala-Gomeza V, Armaroli A, Guglieri M, Straathof CS, Verschuuren JJ, Aartsma-Rus A, Helderman-Van Den Enden P, Bushby K, Straub V, Sewry C, Ferlini A, Ricci E, Morgan JE, Muntoni F (2011) Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 134(12):3544\u20133556. https:\/\/doi.org\/10.1093\/brain\/awr291","journal-title":"Brain"},{"issue":"8","key":"3184_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","volume":"56","author":"S Anwar","year":"2020","unstructured":"Anwar S, Yokota T (2020) Golodirsen for Duchenne muscular dystrophy. Drugs Today (barc, Spain: 1998) 56(8):491\u2013504. https:\/\/doi.org\/10.1358\/dot.2020.56.8.3159186","journal-title":"Drugs Today (barc, Spain: 1998)"},{"issue":"1","key":"3184_CR98","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/jpm11010046","volume":"11","author":"S Anwar","year":"2021","unstructured":"Anwar S, He M, Lim KRQ, Maruyama R, Yokota T (2021) A genotype-phenotype correlation study of exon skip-equivalent in-frame deletions and exon skip-amenable out-of-frame deletions across the DMD gene to simulate the effects of exon-skipping therapies: a meta-analysis. J Pers Med 11(1):46","journal-title":"J Pers Med"},{"issue":"11","key":"3184_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/mt.2010.186","volume":"18","author":"Y Aoki","year":"2010","unstructured":"Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, Takeda S (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 18(11):1995\u20132005. https:\/\/doi.org\/10.1038\/mt.2010.186","journal-title":"Mol Ther"},{"key":"3184_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bcp.13405","volume":"84","author":"JH Beigel","year":"2018","unstructured":"Beigel JH, Voell J, Mu\u00f1oz P, Kumar P, Brooks KM, Zhang J, Iversen P, Heald A, Wong M, Davey RT (2018) Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1 \/ M2 translation. Br J Clin Pharmacol 84:25\u201334. https:\/\/doi.org\/10.1111\/bcp.13405","journal-title":"Br J Clin Pharmacol"},{"key":"3184_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep08986","volume":"5","author":"CA Betts","year":"2015","unstructured":"Betts CA, Saleh AF, Carr CA, Hammond SM, Coenen-Stass AML, Godfrey C, McClorey G, Varela MA, Roberts TC, Clarke K, Gait MJ, Wood MJA (2015) Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Sci Rep 5:1\u20139. https:\/\/doi.org\/10.1038\/srep08986","journal-title":"Sci Rep"},{"issue":"5","key":"3184_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/qjmed\/hcm124","volume":"101","author":"RP Beynon","year":"2008","unstructured":"Beynon RP, Ray SG (2008) Cardiac Involvement in Muscular Dystrophies. QJM 101(5):337\u2013344. https:\/\/doi.org\/10.1093\/qjmed\/hcm124","journal-title":"QJM"},{"issue":"4","key":"3184_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Roy AJ, Chamova T, Guergueltcheva V, Chan S, Korngut L, Campbell C, Dai Y, Wang J, Bari\u0161i\u0107 N, Brabec P, Lahdetie J, Lochm\u00fcller H (2015) The TREAT-NMD DMD global database: Analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 36(4):395\u2013402. https:\/\/doi.org\/10.1002\/humu.22758","journal-title":"Hum Mutat"},{"key":"3184_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198897","author":"AM Blain","year":"2018","unstructured":"Blain AM, Greally E, McClorey G, Manzano R, Betts CA, Godfrey C, O\u2019Donovan L, Coursindel T, Gait MJ, Wood MJ, MacGowan GA, Straub VW (2018) Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-\/-mdx mouse models of Duchenne muscular dystrophy. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0198897","journal-title":"PLoS ONE"},{"key":"3184_CR15","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1542\/peds.2018-0333L","volume":"142","author":"S Buddhe","year":"2018","unstructured":"Buddhe S, Cripe L, Friedland-Little J, Kertesz N, Eghtesady P, Finder J, Hor K, Judge DP, Kinnett K, McNally EM, Raman S, Thompson WR, Wagner KR, Olson AK (2018) Cardiac Management of the patient with Duchenne muscular dystrophy. Pediatrics 142:S72\u2013S81. https:\/\/doi.org\/10.1542\/peds.2018-0333L","journal-title":"Pediatrics"},{"key":"3184_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3233\/JND-160157","volume":"3","author":"MP Carver","year":"2016","unstructured":"Carver MP, Charleston JS, Shanks C, Zhang J, Mense M, Sharma AK, Kaur H, Sazani P (2016) Toxicological characterization of exon skipping phosphorodiamidate morpholino oligomers (PMOs) in non-human primates. J Neuromuscul Dis 3:381\u2013393. https:\/\/doi.org\/10.3233\/JND-160157","journal-title":"J Neuromuscul Dis"},{"issue":"24","key":"3184_CR17","doi-asserted-by":"publisher","first-page":"e2135","DOI":"10.1212\/WNL.0000000000005680","volume":"90","author":"JS Charleston","year":"2018","unstructured":"Charleston JS, Schnell FJ, Dworzak J, Donoghue C, Lewis S, Chen L, David Young G, Milici AJ, Voss J, Dealwis U, Wentworth B, Rodino-Klapac LR, Sahenk Z, Frank D, Mendell JR (2018) Eteplirsen treatment for Duchenne muscular dystrophy. Neurology 90(24):e2135\u2013e2145. https:\/\/doi.org\/10.1212\/WNL.0000000000005680","journal-title":"Neurology"},{"issue":"9791","key":"3184_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","volume":"378","author":"S Cirak","year":"2011","unstructured":"Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJA, Wilton SD, Straub V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet (london, England) 378(9791):595\u2013605. https:\/\/doi.org\/10.1016\/S0140-6736(11)60756-3","journal-title":"Lancet (london, England)"},{"key":"3184_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.gaitpost.2008.06.002","volume":"29","author":"MG D\u2019Angelo","year":"2009","unstructured":"D\u2019Angelo MG, Berti M, Piccinini L, Romei M, Guglieri M, Bonato S, Degrate A, Carla A, Bresolin N (2009) Gait pattern in Duchenne muscular dystrophy. Gait Posture 29:36\u201341. https:\/\/doi.org\/10.1016\/j.gaitpost.2008.06.002","journal-title":"Gait Posture"},{"issue":"2","key":"3184_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ana.25951","volume":"89","author":"Y de Feraudy","year":"2021","unstructured":"de Feraudy Y, Ben Yaou R, Wahbi K, Stalens C, Stantzou A, Laugel V, Desguerre I, Servais L, Leturcq F, Amthor H (2021) Very low residual dystrophin quantity is associated with milder dystrophinopathy. Ann Neurol 89(2):280\u2013292. https:\/\/doi.org\/10.1002\/ana.25951","journal-title":"Ann Neurol"},{"issue":"10","key":"3184_CR21","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.1158\/1078-0432.CCR-04-2091","volume":"11","author":"GR Devi","year":"2005","unstructured":"Devi GR, Beer TM, Corless CL, Arora V, Weller DL, Iversen PL (2005) In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin Cancer Res 11(10):3930\u20133938. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2091","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3184_CR22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1177\/088307388900400402","volume":"4","author":"V Dubowitz","year":"1989","unstructured":"Dubowitz V (1989) The Duchenne dystrophy story: from phenotype to gene and potential treatment. J Child Neurol 4(4):240\u2013250. https:\/\/doi.org\/10.1177\/088307388900400402","journal-title":"J Child Neurol"},{"key":"3184_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/bmj.2.363.541","volume":"2","author":"D Duchenne","year":"1867","unstructured":"Duchenne D (1867) The Pathology of paralysis with muscular degeneration (paralysie myosclerotique), or paralysis with apparent hypertrophy. Br Med J 2:541\u2013542","journal-title":"Br Med J"},{"issue":"1","key":"3184_CR24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/hmg\/7.7.1083","volume":"5","author":"MG Dunckley","year":"1998","unstructured":"Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G (1998) Modification of splicing in the dystrophin gene in cultured mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 5(1):1083\u20131090","journal-title":"Hum Mol Genet"},{"issue":"9","key":"3184_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","volume":"27","author":"K Dzierlega","year":"2020","unstructured":"Dzierlega K, Yokota T (2020) Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Gene Ther 27(9):407\u2013416. https:\/\/doi.org\/10.1038\/s41434-020-0156-6","journal-title":"Gene Ther"},{"issue":"11","key":"3184_CR26","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","volume":"25","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, Mamchaoui K, Aoki Y, Takeda S, Nagaraju K, Mouly V, Maruyama R, Duddy W, Yokota T (2017a) Quantitative antisense screening and optimization FOR Exon 51 skipping in Duchenne Muscular dystrophy. Mol Ther 25(11):2561\u20132572. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.014","journal-title":"Mol Ther"},{"issue":"16","key":"3184_CR27","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T, Urasawa N, Lim KRQ, Trieu N, Panesar D, Kuraoka M, Moulton HM, Saito T, Aoki Y, Iversen P, Sazani P, Kole R, Maruyama R, Partridge T, Takeda S, Yokota T (2017b) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci 114(16):4213\u20134218. https:\/\/doi.org\/10.1073\/pnas.1613203114","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"3184_CR28","first-page":"406","volume":"72","author":"KT Edwards","year":"2017","unstructured":"Edwards KT (2017) The role of patient participation in drug approvals: Lessons from the accelerated approval of eteplirsen. Food Drug Law J 72(3):406\u2013450","journal-title":"Food Drug Law J"},{"key":"3184_CR29","volume-title":"EXONDYS-51 label","author":"FDA","year":"2016","unstructured":"FDA (2016a) EXONDYS-51 label. FDA, Rome"},{"key":"3184_CR30","volume-title":"FDA grants accelerated approval to first drug for Duchenne muscular dystrophy","author":"FDA","year":"2016","unstructured":"FDA (2016b) FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. FDA, Rome"},{"key":"3184_CR31","volume-title":"FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation","author":"FDA","year":"2019","unstructured":"FDA (2019) FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation. FDA, Rome"},{"key":"3184_CR32","volume-title":"FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation","author":"FDA","year":"2020","unstructured":"FDA (2020) FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation. FDA, Rome"},{"key":"3184_CR33","volume-title":"FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation","author":"FDA","year":"2021","unstructured":"FDA (2021) FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation. FDA, Rome"},{"issue":"13","key":"3184_CR34","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1161\/CIR.0000000000000526","volume":"136","author":"B Feingold","year":"2017","unstructured":"Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti AA, Jefferies JL, Judge DP, Lal AK, Markham LW, Parks WJ, Tsuda T, Wang PJ, Yoo SJ (2017) Management of cardiac involvement associated with neuromuscular diseases: a scientific statement from the American Heart Association. Circulation 136(13):e200\u2013e231. https:\/\/doi.org\/10.1161\/CIR.0000000000000526","journal-title":"Circulation"},{"issue":"21","key":"3184_CR35","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","volume":"94","author":"DE Frank","year":"2020","unstructured":"Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, Charleston JS, Sardone V, Domingos J, Dickson G, Straub V, Guglieri M, Mercuri E, Servais L, Muntoni F (2020) Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology 94(21):e2270\u2013e2282. https:\/\/doi.org\/10.1212\/WNL.0000000000009233","journal-title":"Neurology"},{"issue":"1","key":"3184_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2018.0747","volume":"29","author":"MJ Gait","year":"2019","unstructured":"Gait MJ, Arzumanov AA, McClorey G, Godfrey C, Betts C, Hammond S, Wood MJA (2019) Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment. Nucl Acid Ther 29(1):1\u201312. https:\/\/doi.org\/10.1089\/nat.2018.0747","journal-title":"Nucl Acid Ther"},{"issue":"7","key":"3184_CR37","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/mt.2014.63","volume":"22","author":"X Gao","year":"2014","unstructured":"Gao X, Zhao J, Han G, Zhang Y, Dong X, Cao L, Wang Q, Moulton HM, Yin HF (2014) Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice. Mol Therapy 22(7):1333\u20131341. https:\/\/doi.org\/10.1038\/mt.2014.63","journal-title":"Mol Therapy"},{"issue":"2","key":"3184_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.bone.2012.10.036","volume":"52","author":"C Graeff","year":"2013","unstructured":"Graeff C, Marin F, Petto H, Kayser O, Reisinger A, Pe\u00f1a J, Zysset P, Gl\u00fcer C-C (2013) High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA reflects vertebral fracture status in men with glucocorticoid-induced osteoporosis. Bone 52(2):568\u2013577. https:\/\/doi.org\/10.1016\/j.bone.2012.10.036","journal-title":"Bone"},{"key":"3184_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/210797","author":"JD Gumerson","year":"2011","unstructured":"Gumerson JD, Michele DE (2011) The dystrophin-glycoprotein complex in the prevention of muscle damage. J Biomed Biotechnol. https:\/\/doi.org\/10.1155\/2011\/210797","journal-title":"J Biomed Biotechnol"},{"issue":"11","key":"3184_CR40","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1128\/AAC.03442-14","volume":"58","author":"AE Heald","year":"2014","unstructured":"Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, Wong M, Smith WB, Vutikullird A, Kaye E (2014) Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: Results of two single-ascending-dose studies. Antimicrob Agents Chemother 58(11):6639\u20136647. https:\/\/doi.org\/10.1128\/AAC.03442-14","journal-title":"Antimicrob Agents Chemother"},{"key":"3184_CR41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/jgm","volume":"11","author":"HA Heemskerk","year":"2009","unstructured":"Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen G-JB, van Deutekom JCT, Aartsma-Rus A (2009) In vivo comparison of 2\u2019-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11:257\u2013266. https:\/\/doi.org\/10.1002\/jgm","journal-title":"J Gene Med"},{"issue":"3","key":"3184_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","volume":"80","author":"Y-A Heo","year":"2020","unstructured":"Heo Y-A (2020) Golodirsen: first approval. Drugs 80(3):329\u2013333. https:\/\/doi.org\/10.1007\/s40265-020-01267-2","journal-title":"Drugs"},{"key":"3184_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-018-3272-1","author":"N Hilhorst","year":"2018","unstructured":"Hilhorst N, Spanoudi-Kitrimi I, Goemans N, Morren MA (2018) Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study. Eur J Pediatr. https:\/\/doi.org\/10.1007\/s00431-018-3272-1","journal-title":"Eur J Pediatr"},{"issue":"6","key":"3184_CR44","first-page":"919","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: the protein product of the Duchene muscular dystrophy locus. Biotechnology 51(6):919\u2013928","journal-title":"Biotechnology"},{"key":"3184_CR45","unstructured":"Holland A, Gunnoo S, Ching S, Johnson R, Irwin C, Bracegirdle S, Godfrey C (2021) A novel enhanced delivery oligonucleotide (EDO) therapeutic demonstrates considerable potential in treating Duchenne muscular dystrophy"},{"issue":"4","key":"3184_CR46","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/oli.1.1996.6.267","volume":"6","author":"RM Hudziak","year":"1996","unstructured":"Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD (1996) Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucl Acid Drug Dev 6(4):267\u2013272. https:\/\/doi.org\/10.1089\/oli.1.1996.6.267","journal-title":"Antisense Nucl Acid Drug Dev"},{"key":"3184_CR47","first-page":"2510","volume":"9","author":"PL Iversen","year":"2003","unstructured":"Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR (2003) Efficacy of antisense morpholino oligomer targeted to c- myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 9:2510\u20132519","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3184_CR48","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3390\/v4112806","volume":"4","author":"PL Iversen","year":"2012","unstructured":"Iversen PL, Warren TK, Wells JB, Garza NL, Mourich DV, Welch LS, Panchal RG, Bavari S (2012) Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 4(11):2806\u20132830. https:\/\/doi.org\/10.3390\/v4112806","journal-title":"Viruses"},{"issue":"5","key":"3184_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1745-7599.2009.00404.x.Current","volume":"21","author":"R-W Kaspar","year":"2013","unstructured":"Kaspar R-W, Allen HD, Montanaro F (2013) Curren understanding and management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy. J Am Acad Nurse Pract 21(5):241\u2013249. https:\/\/doi.org\/10.1111\/j.1745-7599.2009.00404.x.Current","journal-title":"J Am Acad Nurse Pract"},{"issue":"22","key":"3184_CR50","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1001\/jama.2016.16437","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim AS, Avorn J (2016) Approving a problematic muscular dystrophy drug: implications for FDA policy. J Am Med Assoc 316(22):2357\u20132358. https:\/\/doi.org\/10.1001\/jama.2016.16437","journal-title":"J Am Med Assoc"},{"issue":"2","key":"3184_CR51","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3233\/JND-180351","volume":"6","author":"N Khan","year":"2019","unstructured":"Khan N, Eliopoulos H, Han L, Kinane TB, Lowes LP, Mendell JR, Gordish-Dressman H, Henricson EK, McDonald CM (2019) Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy. J Neuromuscul Dis 6(2):213\u2013225. https:\/\/doi.org\/10.3233\/JND-180351","journal-title":"J Neuromuscul Dis"},{"issue":"10","key":"3184_CR52","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","volume":"8","author":"M Kinali","year":"2009","unstructured":"Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda ME, Rutherford M, McCulley C, Popplewell L, Graham IR, Dickson G, Wood MJA, Wells DJ, Wilton SD, Muntoni F (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8(10):918\u2013928. https:\/\/doi.org\/10.1016\/S1474-4422(09)70211-X","journal-title":"Lancet Neurol"},{"key":"3184_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/JND-170272","volume":"5","author":"TB Kinane","year":"2018","unstructured":"Kinane TB, Mayer OH, Duda PW, Lowes LP, Moody SL, Mendell JR (2018) Longterm pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history. J Neuromuscul Dis 5:47\u201358","journal-title":"J Neuromuscul Dis"},{"key":"3184_CR54","first-page":"184","volume":"31","author":"W Klingler","year":"2012","unstructured":"Klingler W, Jurkat-rott K, Lehmann-horn F, Schleip R (2012) The role of fibrosis in Duchenne muscular dystrophy. Acta Myologica 31:184\u2013195","journal-title":"Acta Myologica"},{"issue":"4","key":"3184_CR55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JND-170280","volume":"4","author":"Z Koeks","year":"2017","unstructured":"Koeks Z, Bladen CL, Salgado D, Van Zwet E, Pogoryelova O, McMacken G, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Bellgard MI, Roy AJ, Chamova T, Guergueltcheva V, Chan S, Korngut L, Campbell C, Lochm\u00fcller H (2017) Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database. J Neuromuscul Dis 4(4):293\u2013306. https:\/\/doi.org\/10.3233\/JND-170280","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"3184_CR56","first-page":"498","volume":"45","author":"M Koenig","year":"1989","unstructured":"Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, M\u00fcller CR, Lindl\u00f6f M, Kaariainen H, de la Chapelle A, Kiuru A, Savontaus ML, Gilgenkrantz H, R\u00e9can D, Chelly J, Kaplan JC, Covone AE, Archidiacono N, Kunkel LM (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45(4):498\u2013506","journal-title":"Am J Hum Genet"},{"issue":"3","key":"3184_CR57","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/dmcn.14129","volume":"61","author":"R Korinthenberg","year":"2019","unstructured":"Korinthenberg R (2019) A new era in the management of Duchenne muscular dystrophy. Dev Med Child Neurol 61(3):292\u2013297. https:\/\/doi.org\/10.1111\/dmcn.14129","journal-title":"Dev Med Child Neurol"},{"key":"3184_CR58","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jpeds.2016.02.067","volume":"173","author":"MM Lamb","year":"2016","unstructured":"Lamb MM, West NA, Ouyang L, Yang M, Weitzenkamp D, James K, Ciafaloni E, Pandya S, Diguiseppi C, Cunniff C, Meaney J, Andrews J, Pettit K, Pettygrove S, Miller L, Matthews D, Montgomery A, Donnelly J, Bolen J, Fox D (2016) Corticosteroid treatment and growth patterns in ambulatory males with Duchenne muscular dystrophy. J Pediatr 173:207-213.e3. https:\/\/doi.org\/10.1016\/j.jpeds.2016.02.067","journal-title":"J Pediatr"},{"issue":"12","key":"3184_CR59","doi-asserted-by":"publisher","first-page":"12140","DOI":"10.1021\/acsnano.8b05721","volume":"12","author":"S Le","year":"2018","unstructured":"Le S, Yu M, Hovan L, Zhao Z, Ervasti J, Yan J (2018) Dystrophin As a Molecular Shock Absorber [Research-article]. ACS Nano 12(12):12140\u201312148. https:\/\/doi.org\/10.1021\/acsnano.8b05721","journal-title":"ACS Nano"},{"issue":"5","key":"3184_CR60","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1093\/nar\/gkt1220","volume":"42","author":"T Lehto","year":"2014","unstructured":"Lehto T, Alvarez AC, Gauck S, Gait MJ, Coursindel T, Wood MJA, Lebleu B, Boisguerin P (2014) Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucl Acids Res 42(5):3207\u20133217. https:\/\/doi.org\/10.1093\/nar\/gkt1220","journal-title":"Nucl Acids Res"},{"key":"3184_CR61","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQ Lim","year":"2017","unstructured":"Lim KRQ, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Dev Ther 11:533\u2013545. https:\/\/doi.org\/10.2147\/DDDT.S97635","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"3184_CR62","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ymthe.2018.10.011","volume":"27","author":"KRQ Lim","year":"2019","unstructured":"Lim KRQ, Echigoya Y, Nagata T, Kuraoka M, Kobayashi M, Aoki Y, Partridge T, Maruyama R, Takeda S, Yokota T (2019) Efficacy of multi-exon skipping treatment in Duchenne muscular dystrophy dog model neonates. Mol Ther 27(1):76\u201386. https:\/\/doi.org\/10.1016\/j.ymthe.2018.10.011","journal-title":"Mol Ther"},{"issue":"9\u201310","key":"3184_CR63","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.nmd.2006.05.017","volume":"16","author":"G McClorey","year":"2006","unstructured":"McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, Fletcher S, Wilton SD (2006a) Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord 16(9\u201310):583\u2013590. https:\/\/doi.org\/10.1016\/j.nmd.2006.05.017","journal-title":"Neuromuscul Disord"},{"issue":"19","key":"3184_CR64","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/sj.gt.3302800","volume":"13","author":"G McClorey","year":"2006","unstructured":"McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD (2006b) Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13(19):1373\u20131381. https:\/\/doi.org\/10.1038\/sj.gt.3302800","journal-title":"Gene Ther"},{"issue":"10119","key":"3184_CR65","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, Clemens PR, Hoffman EP, Cnaan A, Gordish-Dressman H, Vishwanathan V, Chidambaranathan S, Biggar WD, McAdam LC, Mah JK, Tulinius M, Morgenroth LP, Leshner R, Tesi-Rocha C, Karachunski P (2018) Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 391(10119):451\u2013461. https:\/\/doi.org\/10.1016\/S0140-6736(17)32160-8","journal-title":"Lancet"},{"issue":"5","key":"3184_CR66","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Corridore M, Kean JR, Allen HD, Shilling C, Melia KR, Kaye EM (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74(5):637\u2013647. https:\/\/doi.org\/10.1002\/ana.23982","journal-title":"Ann Neurol"},{"issue":"2","key":"3184_CR67","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79(2):257\u2013271. https:\/\/doi.org\/10.1002\/ana.24555","journal-title":"Ann Neurol"},{"issue":"9","key":"3184_CR68","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/21678707.2017.1366310","volume":"5","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Sahenk Z, Rodino-Klapac LR (2017) Clinical trials of exon skipping in Duchenne muscular dystrophy. Expert Opin Orphan Drugs 5(9):683\u2013690. https:\/\/doi.org\/10.1080\/21678707.2017.1366310","journal-title":"Expert Opin Orphan Drugs"},{"key":"3184_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-200548","volume":"1","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Khan N, Sha N, Eliopoulos H, McDonald CM, Goemans N, Mercuri E, Lowes LP, Alfano LN (2021) Comparison of long-term ambulatory function in patients with Duchenne muscular dystrophy treated with eteplirsen and matched natural history controls. J Neuromuscul Dis 1:1\u201311. https:\/\/doi.org\/10.3233\/JND-200548","journal-title":"J Neuromuscul Dis"},{"key":"3184_CR70","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.omtn.2019.01.008","volume":"14","author":"S Miyatake","year":"2019","unstructured":"Miyatake S, Mizobe Y, Tsoumpra MK, Lim KRQ, Hara Y, Shabanpoor F, Yokota T, Takeda S, Aoki Y (2019) Scavenger receptor class A1 mediates uptake of morpholino antisense oligonucleotide into dystrophic skeletal muscle. Mol Therapy Nucl Acids 14:520\u2013535. https:\/\/doi.org\/10.1016\/j.omtn.2019.01.008","journal-title":"Mol Therapy Nucl Acids"},{"issue":"10","key":"3184_CR71","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","volume":"21","author":"SJ Moat","year":"2013","unstructured":"Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L (2013) Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet 21(10):1049\u20131053. https:\/\/doi.org\/10.1038\/ejhg.2012.301","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"3184_CR72","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1021\/bc034221g","volume":"15","author":"HM Moulton","year":"2004","unstructured":"Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL (2004) Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 15(2):290\u2013299. https:\/\/doi.org\/10.1021\/bc034221g","journal-title":"Bioconjug Chem"},{"key":"3184_CR73","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/s0960-8966(18)30304-3","volume":"28","author":"F Muntoni","year":"2018","unstructured":"Muntoni F, Frank DE, Morgan J, Domingos J, Schnell FJ, Dickson G, Popplewell L, Guglieri M, Seferian A, Monforte M, Mercuri E, Servais L, Straub V (2018) Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression in patients with genetic mutations amenable to exon 53 skipping. Neuromuscul Disord 28:S5. https:\/\/doi.org\/10.1016\/s0960-8966(18)30304-3","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"3184_CR74","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1021\/bc0501045","volume":"16","author":"MH Nelson","year":"2005","unstructured":"Nelson MH, Stein DA, Kroeker AD, Hatlevig SA, Iversen PL, Moulton HM (2005) Arginine-rich peptide conjugation to morpholino oligomers: Effects on antisense activity and specificity. Bioconjug Chem 16(4):959\u2013966. https:\/\/doi.org\/10.1021\/bc0501045","journal-title":"Bioconjug Chem"},{"issue":"2","key":"3184_CR75","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","volume":"17","author":"EH Niks","year":"2017","unstructured":"Niks EH, Aartsma-Rus A (2017) Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin Biol Ther 17(2):225\u2013236. https:\/\/doi.org\/10.1080\/14712598.2017.1271872","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"3184_CR76","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/acn3.51149","volume":"7","author":"C Pascual-Morena","year":"2020","unstructured":"Pascual-Morena C, Cavero-Redondo I, \u00c1lvarez-Bueno C, Mesas AE, Pozuelo-Carrascosa D, Mart\u00ednez-Vizca\u00edno V (2020) Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: a systematic review. Ann Clin Transl Neurol 7(9):1738\u20131752. https:\/\/doi.org\/10.1002\/acn3.51149","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"3184_CR77","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1083\/jcb.201212142","volume":"201","author":"F Rahimov","year":"2013","unstructured":"Rahimov F, Kunkel LM (2013) The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy. J Cell Biol 201(4):499\u2013510. https:\/\/doi.org\/10.1083\/jcb.201212142","journal-title":"J Cell Biol"},{"key":"3184_CR78","volume-title":"Clinical update: results from 30 mg \/ kg cohort of momentum study of srp-5051 for Duchenne muscular dystrophy","author":"Sarepta Therapeutics","year":"2021","unstructured":"Sarepta Therapeutics (2021) Clinical update: results from 30 mg \/ kg cohort of momentum study of srp-5051 for Duchenne muscular dystrophy. Sarepta Therapeutics, Cambridge"},{"issue":"2","key":"3184_CR79","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1091581809359206","volume":"29","author":"P Sazani","year":"2010","unstructured":"Sazani P, Weller DL, Shrewsbury SB (2010) Safety pharmacology and genotoxicity evaluation of AVI-4658. Int J Toxicol 29(2):143\u2013156. https:\/\/doi.org\/10.1177\/1091581809359206","journal-title":"Int J Toxicol"},{"issue":"3","key":"3184_CR80","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1091581811403505","volume":"30","author":"P Sazani","year":"2011","unstructured":"Sazani P, Ness KPV, Weller DL, Poage DW, Palyada K, Shrewsbury SB (2011) Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of Duchenne muscular dystrophy. Int J Toxicol 30(3):313\u2013321. https:\/\/doi.org\/10.1177\/1091581811403505","journal-title":"Int J Toxicol"},{"issue":"2","key":"3184_CR81","first-page":"145","volume":"24","author":"Y Shimatsu","year":"2005","unstructured":"Shimatsu Y, Yoshimura M, Yuasa K, Urasawa N, Tomohiro M, Nakura M, Tanigawa M, Nakamura A, Takeda S (2005) Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myol 24(2):145\u2013154","journal-title":"Acta Myol"},{"issue":"7","key":"3184_CR82","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley M (2021) Casimersen: first approval. Drugs 81(7):875\u2013879. https:\/\/doi.org\/10.1007\/s40265-021-01512-2","journal-title":"Drugs"},{"issue":"2","key":"3184_CR83","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/mus.24163","volume":"50","author":"C Spurney","year":"2014","unstructured":"Spurney C, Shimizu R, Morgenroth LP, Kolski H, Gordish-Dressman H, Clemens PR, Cregan M, Goude E, Glick M, Johnson L, Han J, Joyce N, Kilmer D, Nicorici A, Chidambaranathan C, Kumar S, Eliasoph L, Hosaki E, Gonzales A, Zimmerman A (2014) Cooperative international neuromuscular research group Duchenne natural history study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve 50(2):250\u2013256. https:\/\/doi.org\/10.1002\/mus.24163","journal-title":"Muscle Nerve"},{"issue":"3","key":"3184_CR84","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","volume":"7","author":"J Summerton","year":"1997","unstructured":"Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucl Acid Drug Dev 7(3):187\u2013195. https:\/\/doi.org\/10.1089\/oli.1.1997.7.187","journal-title":"Antisense Nucl Acid Drug Dev"},{"key":"3184_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117337","volume":"423","author":"H Takizawa","year":"2021","unstructured":"Takizawa H, Takeshita E, Sato M, Shimizu-Motohashi Y, Ishiyama A, Mori-Yoshimura M, Takahashi Y, Komaki H, Aoki Y (2021) Highly sensitive screening of antisense sequences for different types of DMD mutations in patients\u2019 urine-derived cells. J Neurol Sci 423:117337. https:\/\/doi.org\/10.1016\/j.jns.2021.117337","journal-title":"J Neurol Sci"},{"issue":"9","key":"3184_CR86","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1177\/0883073810371002.Classification","volume":"25","author":"SS Thomas","year":"2013","unstructured":"Thomas SS, Buckon CE, Nicorici A, Bagley A, Mcdonald CM, Sussman MD (2013) Classification of the gait patterns of boys with Duchenne muscular dystrophy and their relationship to function. J Child Neurol 25(9):1103\u20131109. https:\/\/doi.org\/10.1177\/0883073810371002.Classification","journal-title":"J Child Neurol"},{"key":"3184_CR87","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","volume":"45","author":"MK Tsoumpra","year":"2019","unstructured":"Tsoumpra MK, Fukumoto S, Matsumoto T, Takeda S, Wood MJA, Aoki Y (2019) Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. EBioMedicine 45:630\u2013645. https:\/\/doi.org\/10.1016\/j.ebiom.2019.06.036","journal-title":"EBioMedicine"},{"key":"3184_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27347","author":"KR Wagner","year":"2021","unstructured":"Wagner KR, Kuntz NL, Koenig E, East L, Upadhyay S, Han B, Shieh PB (2021) Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.27347","journal-title":"Muscle Nerve"},{"issue":"4","key":"3184_CR90","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMoa1410345","volume":"373","author":"TK Warren","year":"2015","unstructured":"Warren TK, Ph D, Saoud JB, Ph D, Ibrahim MA, Ch B, Wells J, Warfield KL, Ph D, Swenson DL, Ph D, Welch LS, Sazani P, Ph D, Wong M, Berry D, Ph D, Kaye EM, Bavari S, Ph D (2015) AVI-7288 for Marburg virus in nonhuman primates and humans. N Engl J Med 373(4):339\u2013348. https:\/\/doi.org\/10.1056\/NEJMoa1410345","journal-title":"N Engl J Med"},{"issue":"4","key":"3184_CR91","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/BF01799613","volume":"15","author":"RG Worton","year":"1992","unstructured":"Worton RG (1992) Duchenne muscular dystrophy: gene and gene product; mechanism of mutation in the gene. J Inherit Metab Dis 15(4):539\u2013550. https:\/\/doi.org\/10.1007\/BF01799613","journal-title":"J Inherit Metab Dis"},{"issue":"15","key":"3184_CR92","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1093\/nar\/gkm478","volume":"35","author":"RP Wu","year":"2007","unstructured":"Wu RP, Youngblood DS, Hassinger JN, Lovejoy CE, Nelson MH, Iversen PL, Moulton HM (2007) Cell-penetrating peptides as transporters for morpholino oligomers: Effects of amino acid composition on intracellular delivery and cytotoxicity. Nucl Acids Res 35(15):5182\u20135191. https:\/\/doi.org\/10.1093\/nar\/gkm478","journal-title":"Nucl Acids Res"},{"issue":"24","key":"3184_CR93","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1093\/hmg\/ddn293","volume":"17","author":"H Yin","year":"2008","unstructured":"Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P, Wood MJA (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17(24):3909\u20133918. https:\/\/doi.org\/10.1093\/hmg\/ddn293","journal-title":"Hum Mol Genet"},{"issue":"22","key":"3184_CR94","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1093\/hmg\/ddp395","volume":"18","author":"H Yin","year":"2009","unstructured":"Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iverson PL, Wood MJA (2009) A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18(22):4405\u20134414. https:\/\/doi.org\/10.1093\/hmg\/ddp395","journal-title":"Hum Mol Genet"},{"issue":"10","key":"3184_CR95","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/mt.2010.151","volume":"18","author":"H Yin","year":"2010","unstructured":"Yin H, Moulton HM, Betts C, Merritt T, Seow Y, Ashraf S, Wang Q, Boutilier J, Wood MJA (2010) Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol Ther 18(10):1822\u20131829. https:\/\/doi.org\/10.1038\/mt.2010.151","journal-title":"Mol Ther"},{"key":"3184_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/mtna.2013.51","volume":"2","author":"H Yin","year":"2013","unstructured":"Yin H, Boisguerin P, Moulton HM, Betts C, Seow Y, Boutilier J, Wang Q, Lebleu B, Wood MJA (2013) Context dependent effects of chimeric peptide morpholino conjugates contribute to dystrophin exon-skipping efficiency. Mol Ther 2:1\u201310. https:\/\/doi.org\/10.1038\/mtna.2013.51","journal-title":"Mol Ther"},{"issue":"24","key":"3184_CR97","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1212\/WNL.0000000000005669","volume":"90","author":"CD Zingariello","year":"2018","unstructured":"Zingariello CD, Kang PB (2018) Dollars and antisense for Duchenne muscular dystrophy. Neurology 90(24):1091\u20131092. https:\/\/doi.org\/10.1212\/WNL.0000000000005669","journal-title":"Neurology"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-021-03184-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-021-03184-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-021-03184-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T15:34:41Z","timestamp":1659108881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-021-03184-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3184"],"URL":"https:\/\/doi.org\/10.1007\/s00204-021-03184-z","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"22 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TY is a founder and shareholder of OligomicsTx, which aims to commercialize antisense oligonucleotide technology. OS has no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}